Literature DB >> 19013830

Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain.

Michael DeCuypere1, Yan Lu, Duane D Miller, Mark S LeDoux.   

Abstract

Several members of the tetrahydroisoquinoline (TIQ) family of monoamine alkaloids can be formed from dopamine or its oxidized metabolites and may be involved in the pathogenesis of monoaminergic cell death in Parkinson's disease (PD). Using enantiomeric-selective high-performance liquid chromatography with electrochemical detection and liquid chromatography with tandem mass spectroscopy, the regional concentrations of several TIQ derivatives, including salsolinols, were determined in mouse, rat, normal human, and PD brain. TIQ derivatives were detected in all regions subjected to analysis. In general, salsolinols were present at higher concentrations than TIQ and its benzyl and methyl derivatives, especially in human brain. Moreover, salsolinols were concentrated in areas with increased dopamine synthesis and turnover such as the ventral midbrain and striatum, respectively. A possible consequence of nigrostriatal dopaminergic cell death, significantly lower levels of (R)salsolinol, (S)salsolinol, N-methyl-(R)salsolinol and N-methyl-(S)salsolinol were found in the caudate nuclei of PD in comparison with normal human brain. Our data support the hypothesis of endogenous synthesis of salsolinols and provide evidence for their accumulation in catecholaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013830     DOI: 10.1111/j.1471-4159.2008.05709.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

1.  Parkinson disease: calcium channel blockers and Parkinson disease.

Authors:  Ronald F Pfeiffer
Journal:  Nat Rev Neurol       Date:  2010-04       Impact factor: 42.937

Review 2.  Carnosine and Related Peptides: Therapeutic Potential in Age-Related Disorders.

Authors:  José H Cararo; Emilio L Streck; Patricia F Schuck; Gustavo da C Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 3.  A guide to neurotoxic animal models of Parkinson's disease.

Authors:  Kim Tieu
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

4.  Chiral capillary electrophoresis-mass spectrometry of tetrahydroisoquinoline-derived neurotoxins: observation of complex stereoisomerism.

Authors:  Hao Wu; Baiqing Yuan; Yi-Ming Liu
Journal:  J Chromatogr A       Date:  2011-03-21       Impact factor: 4.759

Review 5.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

Review 6.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

7.  Salsolinol, a catechol neurotoxin, induces oxidative modification of cytochrome c.

Authors:  Jung Hoon Kang
Journal:  BMB Rep       Date:  2013-02       Impact factor: 4.778

Review 8.  Salsolinol: an Unintelligible and Double-Faced Molecule-Lessons Learned from In Vivo and In Vitro Experiments.

Authors:  Magdalena Kurnik-Łucka; Pertti Panula; Andrzej Bugajski; Krzysztof Gil
Journal:  Neurotox Res       Date:  2017-10-23       Impact factor: 3.911

9.  Salsolinol-neurotoxic or Neuroprotective?

Authors:  Magdalena Kurnik-Łucka; Gniewomir Latacz; Adrian Martyniak; Andrzej Bugajski; Katarzyna Kieć-Kononowicz; Krzysztof Gil
Journal:  Neurotox Res       Date:  2019-11-15       Impact factor: 3.911

Review 10.  Neurotoxicity and Underlying Mechanisms of Endogenous Neurotoxins.

Authors:  Yanlu Cao; Bo Li; Nafissa Ismail; Kevin Smith; Tianmei Li; Rongji Dai; Yulin Deng
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.